This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

On Friday sullen health indices proved immune to a compelling deluge of post-close earnings the day prior and yet another job slashing.

King Pharmaceuticals (KG) said Thursday after close that it's cutting its workforce by 20% in light of challenges to its Altace franchise and to refocus on neuroscience and hospital/acute care.

In September, the U.S. Court of Appeals ruled against the continued validity of the patent covering blood-pressure drug Altace. (King filed a petition with the court seeking reconsideration of the decision.)

King will incur special charges in 2007 of about $150 million to recognize the impaired value of its intangible assets associated with Altace and about $90 million primarily related to the impaired value of raw material inventory and related contracts associated with Altace. The company estimated that it will also incur a one-time charge of around $70 million during 2007 related to the restructuring, and predicts 2008 savings between $75 million and $90 million from the cut.

Shares edged up 13 cents, or 1.2%, at $10.85. The stock is a component of the Amex pharmaceutical index, which was down 92 cents, or 0.3%, to $347.33.

Intuitive Surgical (ISRG - Get Report) reported Thursday after close that quarterly net income rose to $40.9 million, or $1.04 a share, from $17.3 million, or 45 cents a share, in the prior-year quarter. Revenue rose 64% to $156.9 million from $95.8 million in the third quarter of 2006. Revenue was boosted by a 63% increase in sales of the company's da Vinci Surgical System.

Analysts surveyed by Thomson Financial expected 80 cents a share on revenue of $143.5 million. On Friday HSBC Securities upped its price target for the company to $325 from $198. Shares climbed $22.06, or 8.6%, to $278.50.

Also up was Ventana Medical (VMSI), which late Thursday reported earning $263,000, or a penny a share, compared with $7.8 million, or 22 cents a share, in the year-ago quarter. Excluding special charges and one-time items, the company reported earning $7.9 million, or 22 cents a share. The Thomson Financial consensus target was 19 cents a share on revenue of $73 million.

The company raised its expectations for 2007 adjusted income to around $1.34 a share, compared to its previous prediction of $1.31 a share, and now expects revenue in the range of $296 million to $300 million, up from a previously discussed range of $292 million to $296 million. Shares rose 99 cents, or 1.1%, to $89.30.

In another postclose earnings release Thursday, Gilead (GILD - Get Report) reported net income of $398.3 million, or 42 cents a diluted share, including after-tax stock-based compensation expenses of $31.8 million, compared to a loss of 3 cents in the year-ago quarter. The consensus was 39 cents a share on revenue of $1 billion.

Gilead also named Caroline Dorsa senior vice president and chief financial officer, effective in November to replace John Milligan appointed chief operating officer in March.

Rodman & Renshaw upped its price target for the stock to $56 from $43, but the stock fell $1.32, or 3%, to $42.41 on Friday.

And on Friday morning, Boston Scientific (BSX - Get Report) reported a loss of $272 million, or 18 cents a share, compared to a profit of $76 million, or 5 cents a share, in the year-ago quarter.

But factoring out after-tax acquisition- and divestiture-related charges of $435 million, or 29 cents a share, the company said it earned adjusted income of $299 million, or 20 cents a share, compared to $271 million, or 18 cents a share, on the same basis in the year-ago quarter.

Analysts surveyed by Thomson Financial expected 7 cents a share, on revenue of $2.057 billion. Boston Scientific shares climbed 90 cents, or 6.8%, to $14.74.

In conjunction with Boston Scientific's earnings release, Angiotech Pharmaceuticals (ANPI) gave preliminary results and lowered forecasts.

The company, which makes the paclitaxel coating for the Boston Scientific's drug-eluting stents which prop open clogged arteries, cut its 2007 royalty revenue outlook to a range of $118 million to $120 million compared to prior guidance of $130 million to $135 million. It also lowered its medical product revenue outlook to a range of $171 million to $173 million from $190 million to $210 million.

Angiotech predicted adjusted earnings before interest, taxes, depreciation and amortization of $47 million to $50 million for the year, compared to the prior expectation of $85 million to $95 million. Shares gave up $2.58, or 34.3%, to $4.95.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BSX $17.65 -0.56%
GILD $97.72 -0.42%
ISRG $506.52 0.30%
AAPL $124.25 -0.14%
FB $81.66 -0.67%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs